Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Two proffered paper sessions will highlight results from the ICARUS-BREAST01 phase 2 study of patritumab deruxtecan (HER3-DXd) in patients with HR positive, HER2 negative advanced breast cancer ...

Six late-breaking presentations across lung and breast cancer trials of DXd ADCs, including two Presidential Symposia at WCLC featuring datopotamab deruxtecan data First ever clinical data from ...

Daiichi Sankyo granted Merck exclusive, worldwide rights (excluding Japan) to co-develop and co-commercialize Daiichi's 3 antibody-drug conjugates (ADCs) including patritumab deruxtecan (HER3-DXd ...

Shares of US protein-based vaccine developer Novavax (Nasdaq: NVAX) closed up 8.6% and added a further 1.8% to $12.60 in after-hours trading on Friday, on a positive development for its COVID-19 ...

Merck & Co. is developing a rival B7-H3 ADC with Daiichi. The biotech also discussed its “key products,” namely ADCs aimed at HER3, TROP2 and the autoimmune target BDCA2, plus a bispecific ...

Indian pharma major Sun Pharmaceutical Industries (BSE: 524715) says it has launched tedizolid phosphate tablets 200mg in India under the brand name Starizo. Starizo is a novel, oxazolidinone-class ...